The blockade of both PD-1–PD-L1 and TIM-3–Gal-9 interactions could prevent T-cell exhaustion in advanced acute myelogenous leukemia (AML) as well as reversed T-cell dysfunction and exhaustion in colorectal cancer [122,123]. Here, HAVCR2 is linked to acute myeloid leukemia.